Rachel Abbott
Chief Executive Officer Pan Cancer T
Seminars
Wednesday 20th May 2026
Bringing a Next-Generation Autologous TCR-T-Cell Therapy into the Clinic for Triple Negative Breast Cancer
1:30 pm
- Introducing a first-in-class TCR engineered therapy against a novel target expressed in over 90 percent of triple negative breast cancer and melanoma patients
- Demonstrating how built in co-stimulatory domains within the TCR can enhance T-cell durability while maintaining a compact engineering payload relevant for future in vivo delivery
- Translating promising preclinical data into a cost-effective and scalable clinical manufacturing strategy to unlock cell therapy for hard-to-treat solid tumors
